Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sex differences in the effects of N-ethylpentylone in young CD1 mice: Insights on behaviour, thermoregulation and early gene expression.

Autor: Espinosa-Velasco M; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain., Castro-Zavala A; Neurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Reguilón MD; Unit of Research Psychobiology of Drug Dependence, Department of Psychobiology, Facultad de Psicología, Universitat de Valencia, Valencia, Spain., Gallego-Landin I; Neurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Bellot M; Department of Analytical Chemistry (Chromatography Section), IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain., Rublinetska O; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain., Valverde O; Neurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Rodríguez-Arias M; Unit of Research Psychobiology of Drug Dependence, Department of Psychobiology, Facultad de Psicología, Universitat de Valencia, Valencia, Spain., Nadal-Gratacós N; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain.; Chemical Reactions for Innovative Solutions (CRISOL), IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain., Berzosa X; Chemical Reactions for Innovative Solutions (CRISOL), IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain., Gómez-Canela C; Department of Analytical Chemistry (Chromatography Section), IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain., Carbó ML; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain., Camarasa J; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain., Escubedo E; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain., López-Arnau R; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain., Pubill D; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2024 Nov; Vol. 181 (22), pp. 4491-4513. Date of Electronic Publication: 2024 Jul 16.

Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration.

Autor: Coll S; IMIM (Hospital del Mar Medical Research Institute), Catalonian Antidoping Laboratory, Barcelona, Spain.; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Matabosch X; IMIM (Hospital del Mar Medical Research Institute), Catalonian Antidoping Laboratory, Barcelona, Spain., Llorente-Onaindia J; IMIM (Hospital del Mar Medical Research Institute), Cell Research on Inflammation and Cartilage Group, Barcelona, Spain.; IMIM (Hospital del Mar Medical Research Institute), Rheumatology Department, Barcelona, Spain., Carbó ML; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Pérez-Mañá C; Hospital Universitari Germans Trias i Pujol (IGTP), Department of Clinical Pharmacology, Badalona, Spain.; Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Cerdanyola del Vallès, Spain., Monfort N; IMIM (Hospital del Mar Medical Research Institute), Catalonian Antidoping Laboratory, Barcelona, Spain., Monfort J; IMIM (Hospital del Mar Medical Research Institute), Cell Research on Inflammation and Cartilage Group, Barcelona, Spain.; IMIM (Hospital del Mar Medical Research Institute), Rheumatology Department, Barcelona, Spain., Ventura R; IMIM (Hospital del Mar Medical Research Institute), Catalonian Antidoping Laboratory, Barcelona, Spain.; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.

Publikováno v: Drug testing and analysis [Drug Test Anal] 2019 Nov; Vol. 11 (11-12), pp. 1589-1600. Date of Electronic Publication: 2019 Jun 17.

Metabolomics predicts the pharmacological profile of new psychoactive substances.

Autor: Olesti E; 1 Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.; 2 Department of Experimental and Health Sciences, Pompeu Fabra University (CEXS-UPF), Barcelona, Spain., De Toma I; 2 Department of Experimental and Health Sciences, Pompeu Fabra University (CEXS-UPF), Barcelona, Spain.; 3 Cellular & Systems Neurobiology, Systems Biology Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Ramaekers JG; 4 Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands., Brunt TM; 5 Amsterdam Institute for Addiction Research, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.; 6 Department of Drug Monitoring & Policy, Netherlands Institute of Mental Health and Addiction (Trimbos Institute), Utrecht, The Netherlands., Carbó ML; 2 Department of Experimental and Health Sciences, Pompeu Fabra University (CEXS-UPF), Barcelona, Spain.; 7 Biomedical Research, Prous Institute, Barcelona, Spain.; 8 Department of Pharmacology, Toxicology and Therapeutic Chemistry. Faculty of Pharmacy and Food Sciences, University of Barcelona. Av. Joan XXIII 27-31, Barcelona, Spain., Fernández-Avilés C; 1 Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain., Robledo P; 1 Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.; 2 Department of Experimental and Health Sciences, Pompeu Fabra University (CEXS-UPF), Barcelona, Spain., Farré M; 8 Department of Pharmacology, Toxicology and Therapeutic Chemistry. Faculty of Pharmacy and Food Sciences, University of Barcelona. Av. Joan XXIII 27-31, Barcelona, Spain.; 10 School of Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain., Dierssen M; 1 Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.; 2 Department of Experimental and Health Sciences, Pompeu Fabra University (CEXS-UPF), Barcelona, Spain.; 3 Cellular & Systems Neurobiology, Systems Biology Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.; 10 School of Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.; 11 CIBER de Fisiopatología de la Obesidad y Nutrición (CB06/03), CIBEROBN, Madrid, Spain., Pozo ÓJ; 1 Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain., de la Torre R; 1 Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.; 2 Department of Experimental and Health Sciences, Pompeu Fabra University (CEXS-UPF), Barcelona, Spain.; 10 School of Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.; 11 CIBER de Fisiopatología de la Obesidad y Nutrición (CB06/03), CIBEROBN, Madrid, Spain.

Publikováno v: Journal of psychopharmacology (Oxford, England) [J Psychopharmacol] 2019 Mar; Vol. 33 (3), pp. 347-354. Date of Electronic Publication: 2018 Nov 19.

An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as "bath salts".

Autor: López-Arnau R; Department of Pharmacology and Therapeutic Chemistry, Pharmacology Section, and Institute of Biomedicine, IBUB, Faculty of Pharmacy, University of Barcelona, Spain., Martínez-Clemente J, Carbó Ml, Pubill D, Escubedo E, Camarasa J

Publikováno v: Progress in neuro-psychopharmacology & biological psychiatry [Prog Neuropsychopharmacol Biol Psychiatry] 2013 Aug 01; Vol. 45, pp. 64-72. Date of Electronic Publication: 2013 Apr 18.